ClinicalTrials.gg

Program

PARP1 Inhibitor HS-10502

Also written as “HS-10502 + NHA”, “HS-10502 + HS-20093” and “HS-10502+ Apatinib”.

Its studies are mostly in Ovarian Neoplasms, led by Hansoh Pharmaceutical Group.

Furthest: phase 1, since Feb 14, 20232 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group22 open or runningphase 1since Feb 14, 2023Feb 14, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 14, 2023First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT05740956 · 318 planned · China
  2. Jan 7, 2025Phase 1 study in Ovarian NeoplasmsNCT06769425 · 157 planned · China

TargetBeta

PARP1 →read by rule
“HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor.”study text, by rule · the study

Other programs on PARP1

ProgramCompanyFurthest phaseStudies
olaparibruleAstraZenecaphase 478
niraparibruleGlaxoSmithKlinephase 443
saruparibruleAstraZenecaphase 314
senaparibruleimpact-therapeutics-incphase 212
nesuparibruleJeil Pharmaceuticalphase 24
palacaparibAstraZenecaphase 23
DM5167ruledigmbiophase 11
HSK46256ruleHaisco Pharmaceutical Groupphase 11
TQB3122Sino Biopharmaceuticalphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06769425Ovarian Neoplasms · China1RecruitingMay 7, 2026157
NCT05740956Ovarian Neoplasms · China1RecruitingApr 1, 2026318

How it is read

Names in the registry

  • “HS-10502 + NHA”, 1 entry
  • “HS-10502 + HS-20093”, 1 entry
  • “HS-10502+ Apatinib”, 1 entry
  • “HS-10502 + HS-20089”, 1 entry
  • “HS-10502 + Platinum + Bevacizumab”, 1 entry

Codes read as this program: HS10502.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.